Biotechnology company developing vaccines for infectious diseases, including HIV/AIDS and COVID-19.
GeoVax Labs, Inc., based in Smyrna, Georgia, is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies. Founded in 1988, the company utilizes a robust modified vaccinia ankara virus-like particle vaccine platform to combat infectious diseases and cancers. GeoVax Labs is at the forefront of vaccine research, focusing on a diverse portfolio that includes preventive vaccines for COVID-19, HIV, Zika virus, malaria, and various hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa. Additionally, the company is pioneering therapeutic vaccines targeting HIV, chronic Hepatitis B infections, and solid tumor cancers.
Driven by strategic collaborations and partnerships, GeoVax Labs leverages its scientific expertise and extensive network to accelerate vaccine development. Collaborative agreements with prestigious institutions such as the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), U.S. Department of Defense, Emory University, University of Pittsburgh, and the Burnet Institute bolster its research capabilities and expand its global reach. These partnerships underscore GeoVax Labs' commitment to advancing innovative solutions that address significant public health challenges.
With a rich history spanning decades, GeoVax Labs continues to pioneer breakthroughs in vaccine technology, aiming to transform the landscape of infectious disease prevention and cancer treatment. The company's steadfast dedication to scientific excellence and collaboration underscores its mission to deliver impactful vaccines and immunotherapies that improve health outcomes worldwide.